It began in 1839, inspired by the drive to improve lives of patients. Through our innovative solutions, B. Braun is now one of the leading international health-care providers, while still retaining the core family values that are the foundation of this company.

Since 1991, we have been taking care of renal patients in our global network of renal care centers in Europe, Latin America, Asia and Africa. We provide care to more than 30,000 patients in our centers, understanding their needs and improving their quality of life.

Inspired by this experience and the knowledge we have gained – combined with the constant sharing of expertise we have with our caregivers and patients – is how we continuously develop and improve on the blood purification solutions we provide.

INSPIRED BY SCIENCE
By developing membranes in the dialyzers which fulfill the outcomes required during treatment, namely small- and middle-molecule clearance and albumin retention.

INSPIRED BY TECHNOLOGY
By implementing state-of-the- art research facilities and installing advanced production facilities, B. Braun creates high-performance dialyzers.

INSPIRED BY PATIENTS
By learning from patients and understanding the functionality of the kidney, B. Braun creates dialyzers to improve patient wellbeing.

INSPIRED BY CAREGIVERS
By supporting caregivers to improve on handling and ease-of-use of dialyzers, B. Braun enables time for patient care.

At B. Braun, we don’t just develop products. With our dialyzers, we provide solutions. For life.
By achieving the right balance between elimination and retention, xevonta brings you and your patients the advantages of high flux and hemodiafiltration with high convective volumes.

The focus to date in convective therapy has been on the efficient elimination of uremic toxins. In particular, the subgroup of middle molecules is the subject of considerable medical and scientific discussion. However, attention must also be drawn to substances that should be retained, e.g., proteins such as serum albumin.

IMPORTANCE OF SERUM ALBUMIN
- Marker for nutritional and inflammatory status of maintenance for dialysis patients
- Strong predictor for mortality

In HDF, xevonta allows for efficient elimination of middle molecules and other uremic toxins while limiting the loss of serum albumin to 1.1 ± 0.2 g/session. This is even the case with our largest 2.3 m² surface-area dialyzer, when used under post-dilution HDF conditions using high convective volumes.

### ALBUMIN REMOVAL DURING HDF WITH XEVONTA HI 23

<table>
<thead>
<tr>
<th>Mode</th>
<th>Substitution volume [l]</th>
<th>Ultrafiltration volume [l]</th>
<th>Total convective volume [l]</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-flux HD</td>
<td>0.8 ± 0.2</td>
<td>2.8 ± 0.2</td>
<td>3.6 ± 0.2</td>
</tr>
<tr>
<td>HDF post dilution [10.5 l sub-vol]</td>
<td>10.5 ± 0.2</td>
<td>3.0 ± 0.1</td>
<td>13.5 ± 0.3</td>
</tr>
<tr>
<td>HDF post dilution [18.9 l sub-vol]</td>
<td>18.9 ± 0.4</td>
<td>2.8 ± 0.2</td>
<td>21.7 ± 0.4</td>
</tr>
<tr>
<td>HDF post dilution [21.5 l sub-vol]</td>
<td>21.5 ± 0.5</td>
<td>2.8 ± 0.1</td>
<td>24.3 ± 0.6</td>
</tr>
</tbody>
</table>

### SOURCES

Increased convective volumes. High middle-molecule elimination. High permeability. Low albumin loss.

0.8 ± 0.2 g/session albumin loss for xevonta Hi 18

β₂m reduction rate <0.001 albumin sieving coefficient for xevonta Hi

24.5 ± 0.6 l convective volume for xevonta Hi 18

84% β₂m sieving coefficient for xevonta Hi

124 ml/h/mmHg ultrafiltration coefficient for xevonta Hi 23

<0.001 myoglobin reduction rate for xevonta Hi 23

<0.8 myoglobin reduction rate for xevonta Hi 18

99% ultrafiltration coefficient for xevonta Hi
Diacap Pro
THE TRUSTED PERFORMER

Increasing time for patient care is what the Diacap Pro is inspired to achieve. Combining efficient performance and user-friendly handling, it is the reliable partner in managing your day-to-day needs.

EFFICIENT PERFORMANCE
Improved polysulfone membrane provides high uremic-toxin elimination, which enables patients to efficiently achieve their HD targets.

EASIER HANDLING
Efficient air removal with only 300 ml priming volume. Easy-to-open packaging and improved plugs help nurses to easily and efficiently prepare and perform the treatment.

EFFICIENCY
High in-vitro urea clearance

HANDLING
Only 300 ml priming volume

INNOVATION
Improved α-Polysulfone Pro membrane

PERFORMANCE
High small- and middle-molecule clearance

QUALITY
Designed and manufactured by B. Braun in Germany